Cep America - California

U.S. News & World Report - Los Angeles Metro Best Regional Hospital (2025-26), U.S. News & World Report - High Performing Hospital in Urology (2025-26), U.S. News & World Report - High Performing Hospital in Spinal Fusion (2025-26), Top 100 Oncology Hospitals in the U.S. 2024 - Becker's Hospital Review, American College of Radiology (ACR), Commission on Cancer (CoC) Accreditation - American College of Surgeons (ACS), National Accreditation Program for Breast Centers - American College of Surgeons (ACS), National Accreditation Program for Rectal Cancer Programs - American College of Surgeons (ACS), Accreditation Program for Excellence - American Society for Radiation Oncology (ASTRO)®, Foundation for the Accreditation of Cellular Therapy (FACT), Accountable Care Organizations (ACO) Accreditation - National Committee for Quality Assurance (NCQA), Pancreatic Center of Excellence - National Pancreas Foundation (NPF), Quality Oncology Practice Initiative (QOPI) Certification - American Society of Clinical Oncology (ASCO)

Providence Saint John’s is at the forefront of leading-edge treatment, renowned for our groundbreaking research and turning those discoveries into therapeutics that revolutionize patient care. Our researchers have published approximately 100 peer-reviewed studies across more than a dozen key specialties. Providence Saint John's has hundreds of patients enrolled in dozens of open clinical trials. We have a long history of pioneering clinical trials, research and evidence-based therapies, including leading the international trial of the first immunotherapy approved for melanoma and the first successful gene-engineered T-cell therapy for metastatic pancreatic cancer. Over 1,300 new clinical trials annually, 30+ years of immunotherapy research, 90 years of therapeutic radiation treatment.